Free Trial

Charles Schwab Investment Management Inc. Acquires 153,712 Shares of Celcuity Inc. (NASDAQ:CELC)

Celcuity logo with Medical background

Charles Schwab Investment Management Inc. grew its position in shares of Celcuity Inc. (NASDAQ:CELC - Free Report) by 226.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 221,671 shares of the company's stock after acquiring an additional 153,712 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.60% of Celcuity worth $3,305,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Quest Partners LLC boosted its position in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock worth $95,000 after acquiring an additional 1,379 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Celcuity by 9.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company's stock worth $272,000 after acquiring an additional 1,500 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company's stock worth $361,000 after acquiring an additional 1,600 shares during the last quarter. nVerses Capital LLC acquired a new position in Celcuity during the 3rd quarter worth approximately $33,000. Finally, Prospera Private Wealth LLC acquired a new position in Celcuity during the 3rd quarter worth approximately $35,000. Institutional investors and hedge funds own 63.33% of the company's stock.

Celcuity Stock Performance

CELC traded down $0.09 during trading hours on Friday, reaching $12.52. The company's stock had a trading volume of 114,598 shares, compared to its average volume of 274,980. Celcuity Inc. has a 52 week low of $11.51 and a 52 week high of $22.19. The company's 50-day moving average is $14.34 and its 200-day moving average is $15.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm has a market cap of $464.87 million, a PE ratio of -4.80 and a beta of 0.74.

Analyst Ratings Changes

A number of research firms have weighed in on CELC. HC Wainwright reaffirmed a "buy" rating and set a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Lifesci Capital initiated coverage on Celcuity in a research note on Monday, August 26th. They set an "outperform" rating and a $27.00 price objective on the stock. Finally, Stifel Nicolaus upped their price objective on Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $29.17.

View Our Latest Analysis on Celcuity

About Celcuity

(Free Report)

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Featured Articles

Institutional Ownership by Quarter for Celcuity (NASDAQ:CELC)

Should you invest $1,000 in Celcuity right now?

Before you consider Celcuity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.

While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines